- Home
- PMM vs GOSS Comparison
PMM vs GOSS Comparison
Compare PMM & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMM
- GOSS
- Stock Information
- Founded
- PMM 1989
- GOSS 2015
- Country
- PMM United States
- GOSS United States
- Employees
- PMM N/A
- GOSS N/A
- Industry
- PMM Investment Managers
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- PMM Finance
- GOSS Health Care
- Exchange
- PMM Nasdaq
- GOSS Nasdaq
- Market Cap
- PMM 265.3M
- GOSS 262.5M
- IPO Year
- PMM N/A
- GOSS 2019
- Fundamental
- Price
- PMM $5.89
- GOSS $1.34
- Analyst Decision
- PMM
- GOSS Strong Buy
- Analyst Count
- PMM 0
- GOSS 4
- Target Price
- PMM N/A
- GOSS $7.75
- AVG Volume (30 Days)
- PMM 118.3K
- GOSS 1.3M
- Earning Date
- PMM 01-01-0001
- GOSS 08-11-2025
- Dividend Yield
- PMM 4.68%
- GOSS N/A
- EPS Growth
- PMM N/A
- GOSS N/A
- EPS
- PMM 0.23
- GOSS N/A
- Revenue
- PMM N/A
- GOSS $124,590,000.00
- Revenue This Year
- PMM N/A
- GOSS N/A
- Revenue Next Year
- PMM N/A
- GOSS $91.14
- P/E Ratio
- PMM $26.52
- GOSS N/A
- Revenue Growth
- PMM N/A
- GOSS N/A
- 52 Week Low
- PMM $5.00
- GOSS $0.66
- 52 Week High
- PMM $6.42
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- PMM 48.88
- GOSS 61.44
- Support Level
- PMM $5.86
- GOSS $1.25
- Resistance Level
- PMM $5.93
- GOSS $1.44
- Average True Range (ATR)
- PMM 0.04
- GOSS 0.10
- MACD
- PMM 0.01
- GOSS 0.01
- Stochastic Oscillator
- PMM 63.64
- GOSS 75.00
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.